Sleeping Disease Names: A Complete Glossary of Sleep Disorders

8 min read

Why the Name of a Sleep Disorder Matters

When a doctor says "you have obstructive sleep apnea" rather than "you snore a lot," that distinction carries significant weight. The name of a sleeping disease determines the treatment pathway, the specialist you see, whether a CPAP machine or medication is appropriate, and how your condition is tracked over time.

Sleep medicine has evolved dramatically since polysomnography became clinically available in the 1970s. The International Classification of Sleep Disorders (ICSD-3), published by the American Academy of Sleep Medicine, now recognises more than 60 discrete sleep disorder diagnoses. This glossary covers the conditions Canadians are most likely to encounter, from the extraordinarily common (obstructive sleep apnea affects an estimated 3 million Canadians) to the vanishingly rare (fatal familial insomnia affects fewer than 60 families worldwide).

Understanding the vocabulary helps you navigate conversations with your GP, ask the right questions before a sleep study, and interpret a diagnosis. It also helps you distinguish between conditions that share surface symptoms: excessive daytime sleepiness, for example, can point to half a dozen separate disorders with very different causes and treatments.

This glossary is organised by category, reflecting how the ICSD-3 groups sleep disorders. You will find that the name of each condition often encodes its key features: "obstructive" tells you the mechanism, "delayed sleep phase" tells you the timing problem, "REM sleep behaviour disorder" tells you both the sleep stage and the nature of the disturbance. Learning to read these names is itself a useful clinical skill.

Sleep-Related Breathing Disorders

Obstructive Sleep Apnea (OSA)

Obstructive sleep apnea is the most prevalent sleep disorder in adults. During sleep, the muscles of the throat, tongue, and soft palate relax. In people with OSA, this relaxation is pronounced enough that the upper airway narrows significantly or collapses entirely, cutting off airflow.

Each blockage is called an apnea if it lasts at least 10 seconds with complete cessation of airflow, or a hypopnea if airflow is reduced by at least 30 per cent with associated oxygen desaturation. The brain detects low oxygen and briefly rouses the person to restore muscle tone, a micro-awakening that the sleeper typically does not remember. These arousals can occur dozens to hundreds of times per night, preventing the deep restorative sleep the body needs.

OSA severity is measured by the apnea-hypopnea index (AHI): the number of breathing events per hour. Mild OSA is 5-14 events per hour; moderate is 15-29; severe is 30 or more. Treatment typically involves continuous positive airway pressure (CPAP) therapy, mandibular advancement devices for mild cases, or upper airway surgery in selected patients.

Risk factors include male sex, excess weight, large neck circumference, nasal congestion, and jaw anatomy. However, OSA also occurs in non-obese individuals, women (especially post-menopause), and children with enlarged tonsils or adenoids. The most common symptoms are loud snoring, witnessed gasping or choking episodes during sleep, and excessive daytime sleepiness, though many people with OSA have no memory of nighttime disturbances.

Central Sleep Apnea (CSA)

Central sleep apnea is fundamentally different from OSA. The airway is not blocked. Instead, the brain fails to send the appropriate signal to the breathing muscles. The result is the same (breathing pauses during sleep) but the mechanism is neurological rather than mechanical.

CSA is less common than OSA and is often associated with underlying conditions including heart failure, stroke, brainstem lesions, or opioid medication use. A specific form, Cheyne-Stokes respiration, features a crescendo-decrescendo breathing pattern interspersed with apneas and is strongly associated with congestive heart failure. Treatment of CSA targets the underlying cause where possible, and adaptive servo-ventilation (ASV) devices are used in some cases. Importantly, ASV has been shown to worsen outcomes in heart failure patients with low ejection fraction, illustrating why accurate diagnosis and naming matters so significantly.

Upper Airway Resistance Syndrome (UARS)

UARS sits between simple snoring and OSA. The airway narrows and creates increased resistance, causing effort arousals (brief awakenings driven by respiratory effort) without meeting formal apnea or hypopnea criteria. Patients often present with daytime sleepiness, non-restorative sleep, and sometimes chronic fatigue, but a standard overnight oximetry test may appear normal because oxygen levels do not drop significantly. Diagnosis requires full polysomnography, and the condition often responds well to CPAP therapy.

Hypersomnia Disorders

Narcolepsy Type 1 (NT1)

Narcolepsy type 1 is the full form of narcolepsy, characterised by excessive daytime sleepiness and cataplexy. Cataplexy is a sudden, temporary loss of voluntary muscle tone triggered by strong emotion, such as laughter, surprise, or excitement. During a cataplectic attack the person may slump, drop objects, or collapse entirely while remaining conscious. Attacks typically last seconds to minutes and are specific enough to narcolepsy type 1 that a single clear description of cataplexy is considered diagnostic in context.

The underlying cause of NT1 is now well established: autoimmune destruction of hypocretin-producing neurons in the hypothalamus. Hypocretin (also called orexin) is a neuropeptide that promotes wakefulness and stabilises REM sleep. Its loss means patients struggle to maintain wakefulness during the day and experience intrusions of REM sleep phenomena into waking life, including cataplexy, sleep paralysis, and hypnagogic hallucinations.

Diagnosis requires either a cerebrospinal fluid hypocretin level below 110 pg/mL or a positive multiple sleep latency test (MSLT) showing a mean sleep onset latency of 8 minutes or less with two or more sleep-onset REM periods. Treatment includes wake-promoting agents (modafinil, sodium oxybate, pitolisant), anticataplectics, and scheduled napping.

Narcolepsy Type 2 (NT2)

Narcolepsy type 2 presents with excessive daytime sleepiness and a positive MSLT but without cataplexy and with normal or borderline CSF hypocretin levels. The condition is less well understood than NT1. Some patients with NT2 later develop cataplexy and are reclassified as NT1, suggesting the two may exist on a spectrum. Management focuses on stimulant medications and sodium oxybate in appropriate candidates.

Idiopathic Hypersomnia (IH)

Idiopathic hypersomnia is characterised by excessive daytime sleepiness without the defining features of narcolepsy and without another explanatory cause. The word "idiopathic" means the cause is unknown. Patients typically describe sleep that is long (more than 10 hours), unrefreshing, and accompanied by profound sleep inertia, the difficulty waking and prolonged confusion upon awakening sometimes called "sleep drunkenness."

IH can be significantly disabling. Some patients sleep 12-16 hours per day and still feel exhausted. Recent research has identified a possible role for a naturally occurring GABA-enhancing substance in the cerebrospinal fluid of some IH patients. Calcium oxybate received FDA approval for IH in 2021, though Canadian access varies. Clarithromycin and flumazenil have also shown promise in small studies, and modafinil provides partial benefit for many patients.

Kleine-Levin Syndrome (KLS)

Kleine-Levin syndrome, colloquially known as Sleeping Beauty syndrome, is among the rarest and most dramatic sleep disorders. It is characterised by recurrent episodes of hypersomnia lasting days to weeks, during which a person may sleep 18-20 hours per day. Between episodes, they are entirely normal in function and behaviour.

Episodes are also marked by cognitive disturbances (feeling in a fog, perceiving reality as dreamlike or far away), behavioural changes (irritability, hyperphagia, hypersexuality in some patients), and mood disturbances. The condition predominantly affects adolescent males, though it can occur in females and adults. The cause remains unknown, though post-infectious onset in many cases suggests a possible immune or inflammatory trigger. There is no proven treatment, though lithium has been used to reduce episode frequency in some patients. Episodes typically decrease in frequency over 8-12 years before resolving entirely, though the years of lost time can significantly impact education and social development.

Parasomnias

REM Sleep Behaviour Disorder (RBD)

During normal REM sleep, the body is in a state of muscle atonia, essentially paralysed, which prevents us from acting out our dreams. In REM sleep behaviour disorder, this atonia is absent or incomplete. Patients physically act out their dreams: punching, kicking, shouting, or leaping from bed. Injuries to the patient or their bed partner are common and can be severe.

RBD is clinically significant not only for its immediate dangers but because it is now recognised as a prodromal sign of synucleinopathies, neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Up to 80 per cent of people with idiopathic RBD will eventually develop one of these conditions, sometimes decades after RBD onset. This makes RBD a potential window for early neuroprotective intervention. Diagnosis requires polysomnographic evidence of REM sleep without atonia. Treatment with low-dose clonazepam or melatonin can reduce dream enactment behaviours, and ensuring a safe sleep environment is a practical priority.

NREM Parasomnias: Sleepwalking, Sleep Terrors, and Confusional Arousals

Non-REM parasomnias arise during slow-wave sleep, typically in the first third of the night. They represent incomplete arousal from deep sleep, resulting in a state where motor activity is possible but consciousness is not fully present. Sleepwalking (somnambulism) involves leaving bed and walking, sometimes performing complex behaviours, with no memory of the event upon awakening. Sleep terrors (pavor nocturnus) involve sudden arousal with intense fear, screaming, and autonomic activation, with typically no recall in the morning. Confusional arousals involve disorientation and confused behaviour after awakening, without leaving the bed.

NREM parasomnias are more common in children and often resolve with age. In adults they can be triggered or worsened by sleep deprivation, stress, fever, alcohol, or sedative-hypnotic medications. Safety measures and improving overall sleep quality are the primary management approaches.

Movement Disorders

Restless Legs Syndrome (RLS)

Restless legs syndrome is a sensorimotor disorder defined by four essential criteria established by the International RLS Study Group: an urge to move the legs (sometimes accompanied by uncomfortable sensations described as crawling, pulling, tingling, or aching); the urge worsening at rest; partial or complete relief with movement; and symptoms being worse in the evening or at night.

RLS is a waking disorder. It occurs before sleep, not during it. The discomfort compels movement, which delays sleep onset and makes the rest that does occur fragmentary and unrefreshing. RLS affects an estimated 5-10 per cent of Canadians and has a strong genetic component, with first-degree relatives having a 3-5 times higher risk. It is also associated with iron deficiency, pregnancy, kidney failure, and peripheral neuropathy.

Iron supplementation is first-line treatment when serum ferritin is below 75 mcg/L. Dopaminergic medications, alpha-2 delta ligands (gabapentin, pregabalin), and benzodiazepines are also used. A notable complication of long-term dopaminergic therapy is augmentation, a paradoxical worsening of symptoms in which the condition spreads to other body parts or occurs earlier in the day, requiring careful management by an experienced clinician.

Periodic Limb Movement Disorder (PLMD)

Periodic limb movement disorder occurs during sleep rather than before it, and the person is usually unaware of it. PLMD involves repetitive, stereotyped limb movements (typically dorsiflexion of the foot, extension of the big toe, and flexion of the knee and hip) occurring in clusters during NREM sleep, often every 20-40 seconds throughout the night. A bed partner may notice the movements; the patient often reports unrefreshing sleep without knowing why.

While periodic limb movements during sleep are a common polysomnography finding (especially in older adults), PLMD as a diagnosis is only made when these movements cause clinically significant sleep disturbance or daytime impairment and when another disorder such as RLS does not better explain them. Treatment when warranted is similar to RLS: dopaminergic agents or alpha-2 delta ligands.

Circadian Rhythm Sleep-Wake Disorders

Delayed Sleep Phase Disorder (DSPD)

Delayed sleep phase disorder represents a stable, significant delay in the timing of the circadian clock. People with DSPD have a naturally late chronotype pushed to an extreme: they cannot fall asleep until 2-6 am and find it nearly impossible to wake before 10 am-2 pm without severe impairment. DSPD is not a matter of preference or poor discipline. It is a biological mismatch between the internal clock and social demands. When allowed to sleep on their natural schedule, people with DSPD sleep normally in duration and quality.

The disorder is more common in adolescents and young adults, affects an estimated 0.15 per cent of the general population, and has a genetic basis involving polymorphisms in clock genes such as CRY1. Treatment includes timed bright light therapy (morning exposure to advance the clock), chronotherapy (progressively delaying sleep time until the desired schedule is reached and then holding it), and low-dose melatonin taken in the early evening to phase-advance the clock before the desired bedtime.

Advanced Sleep Phase Disorder (ASPD)

The mirror image of DSPD, advanced sleep phase disorder involves a circadian clock that runs early. People with ASPD feel compelled to sleep by 6-9 pm and wake spontaneously at 2-5 am, fully refreshed but facing a social and professional world that operates on later hours. ASPD is more common in older adults. Mutations in the PER2 and CKI-delta genes have been identified in familial cases. Evening bright light therapy (exposure at 7-9 pm to delay the clock) is the primary treatment.

Non-24-Hour Sleep-Wake Disorder (N24)

Non-24-hour sleep-wake disorder occurs when the circadian clock fails to entrain to the 24-hour day. Instead of being reset by morning light each day, the clock drifts, usually lengthening by 30-60 minutes per day. The result is that sleep and wake times cycle gradually around the clock over weeks: a person might sleep midnight-8 am one week, then 3 am-11 am the next, then 6 am-2 pm, and so on. N24 is most prevalent among blind individuals who lack the photic input that entrains the clock, but also occurs in some sighted individuals, often with DSPD as a precursor. Tasimelteon (Hetlioz), a melatonin receptor agonist, is approved for N24 in blind adults.

Shift Work Sleep Disorder

Shift work sleep disorder develops in people whose work schedules conflict with their natural sleep time, resulting in insomnia when they try to sleep and excessive sleepiness during working hours. It is classified as a circadian rhythm disorder because the root cause is misalignment between the internal clock and the required sleep-wake schedule. An estimated 10-38 per cent of shift workers develop the disorder. Management focuses on sleep hygiene strategies around shifts, strategic bright light exposure, and in some cases modafinil or armodafinil for shift-work sleepiness.

Rare and Severe Sleep Disorders

Fatal Familial Insomnia (FFI)

Fatal familial insomnia is among the most devastating and medically significant sleep disorders known. It is a rare prion disease caused by a mutation in the PRNP gene on chromosome 20. Only about 60 families worldwide have been identified with the mutation, though a sporadic (non-familial) form has been reported in individuals without the family history.

FFI typically begins in middle age with progressive, untreatable insomnia. As the thalamus, the brain region that regulates sleep, is progressively destroyed by misfolded prion protein accumulation, the ability to sleep deteriorates completely. The disease progresses through stages: initial insomnia accompanied by anxiety and panic attacks; escalating insomnia with hallucinations; complete insomnia with rapid dementia; and finally near-total loss of verbal and motor function before death. Death typically occurs within 12-18 months of symptom onset. There is currently no effective treatment, and FFI remains universally fatal.

Idiopathic Insomnia

Most insomnia is comorbid with another condition such as depression, anxiety, chronic pain, or substance use. Idiopathic insomnia, by contrast, is a lifelong difficulty initiating or maintaining sleep that begins in childhood and persists through adulthood without an identifiable precipitating cause. It is thought to reflect a neurological hyperarousal trait present from birth. Cognitive behavioural therapy for insomnia (CBT-I) is the evidence-based first-line treatment for all forms of chronic insomnia, including the idiopathic subtype.

Sleep Paralysis (Isolated Recurrent)

Sleep paralysis is the experience of being unable to move or speak during the transition between sleep and wakefulness. It is a normal REM atonia intrusion occurring in the opposite direction to RBD. Most adults experience it at least once. Recurrent isolated sleep paralysis, occurring frequently and causing significant distress, is a diagnosable condition often accompanied by vivid, threatening hallucinations and intense fear. Sleep deprivation, irregular sleep schedules, and stress increase the frequency of episodes.

Getting Diagnosed in Canada

Wait times for sleep specialist appointments vary significantly across Canadian provinces. Ontario and British Columbia have the most established sleep medicine infrastructure; rural and remote areas face considerably longer waits. If you suspect OSA specifically, asking your GP about a home sleep apnea test can accelerate the path to diagnosis, as HSAT is often arranged more quickly than in-lab studies and is equally accurate for straightforward OSA cases.

Many sleep disorders go undiagnosed for years. OSA is estimated to be undiagnosed in approximately 80 per cent of those who have it. RLS is frequently misdiagnosed as anxiety, growing pains, or peripheral neuropathy. DSPD is consistently misattributed to poor sleep habits or laziness, particularly in adolescents who face particular social stigma for being unable to function in the morning. Knowing the names and characteristic features of these conditions puts you in a significantly stronger position to advocate for appropriate investigation.

Frequently Asked Questions

What is the difference between OSA and central sleep apnea?

Obstructive sleep apnea (OSA) occurs when throat muscles relax and physically block the airway during sleep. Central sleep apnea (CSA) occurs when the brain fails to send proper signals to the muscles that control breathing. OSA is far more common and treated with CPAP therapy; CSA often requires addressing an underlying neurological or cardiac condition.

What is Kleine-Levin syndrome?

Kleine-Levin syndrome, sometimes called Sleeping Beauty syndrome, is a rare disorder characterised by recurring episodes of excessive sleep lasting days to weeks, along with cognitive impairment and altered behaviour. Between episodes, affected individuals function completely normally. Episodes can recur over years before resolving spontaneously.

Is restless legs syndrome the same as periodic limb movement disorder?

No. RLS is a waking sensory disorder, an urge to move the legs with uncomfortable sensations, worse at rest and in the evening. PLMD involves involuntary limb jerks that occur during sleep and that the person is typically unaware of. The two conditions overlap but are distinct diagnoses requiring different evaluation approaches.

What is delayed sleep phase disorder (DSPD)?

DSPD is a circadian rhythm disorder in which the internal biological clock is shifted significantly later than conventional sleep schedules. People with DSPD cannot fall asleep until 2-6 am and struggle to wake for morning obligations, but sleep normally in duration and quality when allowed to follow their natural schedule.

Can a mattress help with sleep disorders?

A mattress cannot treat a diagnosed sleep disorder, but the right sleep surface can reduce secondary discomfort and support better rest. For RLS and PLMD, a mattress with good motion isolation helps a partner sleep undisturbed. For sleep apnea, an adjustable base that elevates the head can reduce airway obstruction. Visiting a qualified sleep specialist remains essential for a proper diagnosis and treatment plan.

Visit Our Brantford Showroom

We are located at 441½ West Street in downtown Brantford. Free parking available. Our team does not work on commission, so you get honest advice based on your needs.

Mattress Miracle — 441½ West Street, Brantford, ON — (519) 770-0001

Hours: Monday–Wednesday 10am–6pm, Thursday–Friday 10am–7pm, Saturday 10am–5pm, Sunday 12pm–4pm.

If a sleep disorder is affecting your quality of rest, come speak with us about sleep surfaces that can support you while you pursue a proper diagnosis. We carry adjustable bases, pressure-relieving mattresses, and pillows designed to help with specific sleep challenges.